About EMLA
EMLA is the first topical anaesthetic able to numb intact skin prior to needle insertion procedures and superficial surgical procedures.
EMLA is the only topical anaesthetic with proven efficacy of all three indications intact skin, genital mucous membranes and leg ulcers. The unique pharmaceutical formulation makes EMLA a more effective topical anaesthetic of intact skin than single-component lidocaine formulations.
Quick guide to EMLA
The quick guide to EMLA is a short guide to EMLA anaesthetic times, dosages and prescribing information.
This is EMLAEMLA Cream (lidocaine 2.5 mg/g and prilocaine 2.5 mg/g) is an emulsion in which the oil phase is a eutectic mixture of the local anaesthetics lidocaine and prilocaine in a ratio of 1:1 by weight. This eutectic mixture has a melting point below room temperature and therefore the local anaesthetics exist as an oil rather then as crystals. Being an oil, no lipophilic solvent is required which ensures the rapid release of local anaesthetics from the emulsion and the highest concentration possible in the aqueous phase. These characteristics allow the drug to penetrate the dermal layers of the skin more effectively than single-component creams. When applied on intact skin or leg ulcers, EMLA cream should be covered with an occlusive dressing, which facilitates the percutaneous absorption. EMLA cream is packaged in 5 gram and 30 gram tubes. EMLA patch contains a single unit-dose of 1 g EMLA in a ready-to-use adhesive which provides anaesthesia of a circular skin area of about 10 cm2 |
Page tools
AstraZeneca Events
Contact us
Information for
This is an AstraZeneca International website for healthcare professionals and is not intended for the following audiences who should use the links below:
